Article Sidebar
Views PDF: 204
CONSTRUCT THE MODEL OF COST– EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB VERSUS STANDARD THERAPY IN THE TREATMENT OF MULTIPLE MYELOMA IN VIETNAM
Main Article Content
Abstract
Lung cancer is one of the most common cancers and the leading cause of cancer death in many countries around the world as well as in Vietnam, in which non-small cell lung cancer accounts for 80 – 85% [1]. Atezolizumab was approved by the Food and Drug Administration (FDA) in 2020 for the treatment of non-small cell lung cancer (NSCLC). Besides the effectiveness and safety of the drug, the choice of treatment regimen depends on the cost-effectiveness of the intervention, from which the establishment of cost – effectiveness analysis model is considered to be one of the most important steps to determine the feasibility and reliability of the analysis. By modeling method, literature review and clinical expert consultation, the CEA model in the treatment of NSCLC has been built using Microsoft Excel 2016 software with a model structure including calculation pages for output parameters (cost-effectiveness, sensitivity index) to access feasibility in clinical drug selection. The model allows cost-effectiveness analysis of atezolizumab compared with standard regimens in the treatment of NSCLC in Vietnam.
Article Details
Keywords
Cost – effectiveness, model, atezolizumab, non small-cell lung cancer
References
2. Dong D., Huabin H., Mengting L. et al. (2020), “Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non- Small Cell Lung Cancer", Adv Ther, 37(5), pp. 2116-2126.
3. Gouqiang L., Shuo K., Xinchen W. et al. (2021), "Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status", Front Oncol, 11(669195).
4. Shen L., Shaohong L., Lixian Z. et al. (2020), “Cost-effectiveness of atezolizumab plus chemotherapy for advanced non-small-cell lung cancer", Int J Clin Pharm, 42 (4), pp. 1175-1183.
5. Sivignon M., Roze S., Plommet M. et al. (2020), "Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France", Journal of Medical Economics, 23(5), pp. 464-473.
6. Steven D., Meghan J., Tina R. et al. (2019), "Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States", JAMA Netw Open, 2(9), e1911952.
7. Umang O., H. J., Scott O. et al. (2019), "Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC)", Journal of Medical Economics, 22(7), pp. 625-637.
8. XiaoMin W., Xia L., ChongQing T. et al. (2019), “First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis”, Cancer, 125(20), pp. 3526-3534.
9. Rittmeyer A., Waterkamp D., Park K. et al. (2017), “Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial”, Lancet, 389(10066), pp. 255-65.